Immune-Onc Therapeutics is a clinical-stage developer of novel biotherapeutics for cancer patients.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/06/2023 | Series B3 | $30MM | $xx.xx | $26.22B | Proxima Ventures, Triwise Capital | |
Price per Share
$xx.xx
Shares Outstanding
14,211,880
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Proxima Ventures, Triwise Capital
|
||||||
03/30/2021 | Series B2 | $12.9MM | $xx.xx | $19.06B | Northern Light Venture Capital, Oceanpine Capital, Octagon Capital, Sphera Healthcare, Vivo Capital | |
Price per Share
$xx.xx
Shares Outstanding
9,999,484
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Northern Light Venture Capital, Oceanpine Capital, Octagon Capital, Sphera Healthcare, Vivo Capital
|
||||||
03/30/2021 | Series B1 | $60MM | $xx.xx | $19.06B | Northern Light Venture Capital, Oceanpine Capital, Octagon Capital, Sphera Healthcare, Vivo Capital | |
Price per Share
$xx.xx
Shares Outstanding
37,220,843
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Northern Light Venture Capital, Oceanpine Capital, Octagon Capital, Sphera Healthcare, Vivo Capital
|
||||||
09/18/2018 | Series B | $33.25MM | $xx.xx | $9.39B | Northern Light Venture Capital, Stanford-Startx Fund, Vivo Capital | |
Price per Share
$xx.xx
Shares Outstanding
20,988,105
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Northern Light Venture Capital, Stanford-Startx Fund, Vivo Capital
|
||||||
09/01/2016 | Series A | $7MM | $xx.xx | $2.33B | Cli Ventures, Fame Mount Limited | |
Price per Share
$xx.xx
Shares Outstanding
8,634,934
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cli Ventures, Fame Mount Limited
|